logo

dr-james-hawkins

  • icon-cloud
  • icon-facebook
  • icon-feed
  • icon-feed
  • icon-feed

Leeds BABCP conference: workshop on emotion processing in chronic fatigue syndrome - current CBT treatment results (2nd post)

In yesterday's post, I described the pre-workshop publicity for this day on treatment of chronic fatigue syndrome.  How did I find the workshop in actual practice? Well, I enjoyed meeting Trudie Chalder. She came across as very alive, friendly, bright, knowledgeable. Great.  And her two decades or so of dedicated exploration of Chronic Fatigue Syndrome is so impressive ... one of those research journeys that I find it heart-warming to look at.  For me the workshop itself was a bit of a funny mix. In the morning session we were given an overview/update on chronic fatigue syndrome and its standard CBT treatment.

Leeds BABCP conference: pre-conference workshop on emotion processing in chronic fatigue syndrome with Trudie Chalder (1st post)

The 40th British Association for Behavioural & Cognitive Psychotherapies (BABCP) conference is at Leeds University.  As usual it's preceded by a choice of pre-conference workshops. Three of the nineteen initially on offer have been cancelled, but there's still a wealth of options. I'm due to go to Trudie Chalder, from the London Institute of Psychiatry, speaking on "Emotional Processing in the Context of Chronic Fatigue Syndrome and Implications for Persistent Physical Symptoms in General".  The pre-workshop publicity states: "More than half of people with chronic fatigue syndrome (CFS) have co-morbid depression or anxiety.

Purpose in life: reduces dementia risk, increases life expectancy, treats depression and builds wellbeing

I was struck by a paper published this month in the journal Archives of General Psychiatry - "Effect of purpose in life on the relation between Alzheimer disease pathologic changes on cognitive function in advanced age".  The authors wrote "In recent years, systematic examination has shown that purpose in life is associated with a substantially reduced risk of incident AD (Alzheimer disease), mild cognitive impairment, disability, and death.